The analysis focuses on Pfizer (PFE), currently priced at $24.03. Over the past five years, the stock has seen a 29% decline. However, the dividend yield is currently at 7%, making it attractive given lower interest rates. The recent earnings report was positive, with earnings per share exceeding expectations (78 cents vs. 58 cents expected) and strong revenue growth. Oncology sector growth is highlighted. The analysis states new products see a 15% revenue increase. Guidance for 2025 is positive, raising EPS estimates from $2.80-$3.00 to $2.90-$3.10. The company aims to maintain and grow dividends, reinvest in R&D, and de-leverage its balance sheet, but has not been buying back stock to create value for shareholders. High debt levels, $6 billion due in 2026, are limiting buybacks. The expectation is that future debt will lower due to current management, which could change the strategy. Free cash flow yield is 11%, while the dividend payout ratio is 65-68%. The analysis expects a significant increase in free cash flow from $12 billion to $19 billion by 2027, while current revenues are in line with those estimated, which are expected to lower the company’s need to spend. The average historical P/E ratio is around 12.85, but is at 8.67.The stock may trade around 11-13% annually.